TY - JOUR
T1 - Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans
AU - Stepien, Magdalena
AU - Hughes, David J.
AU - Hybsier, Sandra
AU - Bamia, Christina
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Affret, Aurélie
AU - His, Mathilde
AU - Boutron-Ruault, Marie Christine
AU - Katzke, Verena
AU - Kühn, Tilman
AU - Aleksandrova, Krasimira
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Orfanos, Phlippos
AU - Palli, Domenico
AU - Sieri, Sabina
AU - Tumino, Rosario
AU - Ricceri, Fulvio
AU - Panico, Salvatore
AU - Bueno-de-Mesquita, H. Bas
AU - Peeters, Petra H.
AU - Weiderpass, Elisabete
AU - Lasheras, Cristina
AU - Bonet Bonet, Catalina
AU - Molina-Portillo, Elena
AU - Dorronsoro, Miren
AU - Huerta, José María
AU - Barricarte, Aurelio
AU - Ohlsson, Bodil
AU - Sjöberg, Klas
AU - Werner, Mårten
AU - Shungin, Dmitry
AU - Wareham, Nick
AU - Khaw, Kay Tee
AU - Travis, Ruth C.
AU - Freisling, Heinz
AU - Cross, Amanda J.
AU - Schomburg, Lutz
AU - Jenab, Mazda
N1 - Publisher Copyright:
© 2017 Cancer Research UK. All rights reserved.
PY - 2017/2/28
Y1 - 2017/2/28
N2 - Background:Copper and zinc are essential micronutrients and cofactors of many enzymatic reactions that may be involved in liver-cancer development. We aimed to assess pre-diagnostic circulating levels of copper, zinc and their ratio (Cu/Zn) in relation to hepatocellular carcinoma (HCC), intrahepatic bile duct (IHBD) and gall bladder and biliary tract (GBTC) cancers.Methods:A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort. Serum zinc and copper levels were measured in baseline blood samples by total reflection X-ray fluorescence in cancer cases (HCC n=106, IHDB n=34, GBTC n=96) and their matched controls (1:1). The Cu/Zn ratio, an indicator of the balance between the micronutrients, was computed. Multivariable adjusted odds ratios and 95% confidence intervals (OR; 95% CI) were used to estimate cancer risk.Results:For HCC, the highest vs lowest tertile showed a strong inverse association for zinc (OR=0.36; 95% CI: 0.13-0.98, P trend =0.0123), but no association for copper (OR=1.06; 95% CI: 0.45-2.46, P trend =0.8878) in multivariable models. The calculated Cu/Zn ratio showed a positive association for HCC (OR=4.63; 95% CI: 1.41-15.27, P trend =0.0135). For IHBC and GBTC, no significant associations were observed.Conclusions:Zinc may have a role in preventing liver-cancer development, but this finding requires further investigation in other settings.
AB - Background:Copper and zinc are essential micronutrients and cofactors of many enzymatic reactions that may be involved in liver-cancer development. We aimed to assess pre-diagnostic circulating levels of copper, zinc and their ratio (Cu/Zn) in relation to hepatocellular carcinoma (HCC), intrahepatic bile duct (IHBD) and gall bladder and biliary tract (GBTC) cancers.Methods:A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort. Serum zinc and copper levels were measured in baseline blood samples by total reflection X-ray fluorescence in cancer cases (HCC n=106, IHDB n=34, GBTC n=96) and their matched controls (1:1). The Cu/Zn ratio, an indicator of the balance between the micronutrients, was computed. Multivariable adjusted odds ratios and 95% confidence intervals (OR; 95% CI) were used to estimate cancer risk.Results:For HCC, the highest vs lowest tertile showed a strong inverse association for zinc (OR=0.36; 95% CI: 0.13-0.98, P trend =0.0123), but no association for copper (OR=1.06; 95% CI: 0.45-2.46, P trend =0.8878) in multivariable models. The calculated Cu/Zn ratio showed a positive association for HCC (OR=4.63; 95% CI: 1.41-15.27, P trend =0.0135). For IHBC and GBTC, no significant associations were observed.Conclusions:Zinc may have a role in preventing liver-cancer development, but this finding requires further investigation in other settings.
UR - http://www.scopus.com/inward/record.url?scp=85011617240&partnerID=8YFLogxK
U2 - 10.1038/bjc.2017.1
DO - 10.1038/bjc.2017.1
M3 - Article
C2 - 28152549
AN - SCOPUS:85011617240
SN - 0007-0920
VL - 116
SP - 688
EP - 696
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -